La vendita allo scoperto per Enanta Pharma dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Enanta Pharma. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Enanta Pharma (NASDAQ:ENTA) Azioni, Report sulle vendite allo scoperto

Enanta Pharma

Enanta Pharmaceuticals Inc is an American biotechnology company focused on the research and development of molecule drugs to cure viral infections and liver diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.

Enanta Pharmaceuticals, Inc. - Common Stock

Enanta Pharmaceuticals Inc

Entain PLC

HC Wainwright &amp; Co. analyst Ed Arce reiterates Enanta Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTA#NASDAQ">ENTA</a>) with a Buy and maintains $27 price target.

News

Price Target

Reiteration

Analyst Ratings

ENTA

HC Wainwright & Co. Reiterates Buy on Enanta Pharma, Maintains $27 Price Target

4 analysts have shared their evaluations of Enanta Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTA#NASDAQ">ENTA</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $20.25, along with a high estimate of $27.00 and a low estimate of $10.00. A decline of 1.22% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2024/1728500522_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
A comprehensive examination of how financial experts perceive Enanta Pharma is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Roy Buchanan</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$22.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Roy Buchanan</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$22.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Eric Joseph</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$10.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Ed Arce</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$27.00</td>
<td>$27.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Enanta Pharma. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Enanta Pharma compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Enanta Pharma's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Enanta Pharma's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ENTA/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Enanta Pharma analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Discovering Enanta Pharma: A Closer Look</h2>
Enanta Pharmaceuticals Inc is an American biotechnology company focused on the research and development of molecule drugs to cure viral infections and liver diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.
<h3>A Deep Dive into Enanta Pharma's Financials</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Decline in Revenue: Over the 3 months period, Enanta Pharma faced challenges, resulting in a decline of approximately -4.88% in revenue growth as of 30 June, 2024. This signifies a reduction in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Enanta Pharma's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -126.08%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Enanta Pharma's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -14.38%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Enanta Pharma's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -5.58%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.34.
<h2>The Basics of Analyst Ratings</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Glimpse Into The Expert Outlook On Enanta Pharma Through 4 Analysts

JMP Securities analyst Roy Buchanan reiterates Enanta Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTA#NASDAQ">ENTA</a>) with a Market Outperform and maintains $22 price target.

JMP Securities Reiterates Market Outperform on Enanta Pharma, Maintains $22 Price Target

Enanta Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTA#NASDAQ">ENTA</a>) released on Thursday topline results from a Phase 2a human challenge study of EDP-323 in healthy adults infected with respiratory syncytial virus (RSV).
The data demonstrated that EDP-323 was generally safe and well-tolerated and achieved an 85%-87% reduction in viral load area under the curve (AUC), a 97%-98% reduction in infectious viral load AUC by viral culture, and a 66%-78% reduction of total clinical symptoms score AUC compared to placebo.
EDP-323 lowered viral load AUC by 85% in the high-dose arm and 87% in the low-dose arm compared to placebo. There was no statistically significant difference between the two EDP-323 dosing groups.
EDP-323 received an FDA Fast Track designation. It is a novel L-protein inhibitor being developed as a once-daily oral treatment for RSV.
EDP-323 demonstrated favorable pharmacokinetics, supporting once-daily dosing. Mean trough plasma concentrations were maintained at 16-fold above the protein-adjusted EC90&nbsp;with the low dose and 35-fold above the protein-adjusted EC90&nbsp;with the high dose for both RSV A and B strains.
Overall, EDP-323 demonstrated a favorable safety profile over a five-day dosing period and through 28 days of follow-up. Adverse events were similar between EDP-323 dosing groups and placebo.
Enanta has another RSV treatment under development, zelicapavir, the company&#8217;s lead oral N-protein inhibitor.
Zelicapavir is being evaluated in two Phase 2 clinical trials in high-risk pediatric <a target="_blank" href="https://www.benzinga.com/pressreleases/24/08/b40170540/enanta-pharmaceuticals-reports-financial-results-for-its-fiscal-third-quarter" rel="noreferrer noopener">and adult populations</a>.
ENTA Price Action: Enanta Pharmaceuticals stock is down 1.83% at $10.48 at publication Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/41052867/disneys-streaming-surge-epic-games-deal-among-key-growth-drivers-says-analyst" target="_blank" rel="noreferrer noopener">Disney&#8217;s Streaming Surge, Epic Games Deal Among Key Growth Drivers, Says Analyst</a>.</li>
</ul>
Photo: Shutterstock

Biotech

Health Care

General

Enanta Pharmaceuticals Reports Antiviral For Respiratory Syncytial Virus Reduces Virus Levels, Symptoms In Study

Enanta Pharmaceuticals' Phase 2A Human Challenge Study Of EDP-323 In Healthy Adults Infected With Respiratory Syncytial Virus, Met Primary And Secondary Endpoints, Achieving Statistically Significant Reductions In Both Viral Load And Clinical Symptoms Compared To Placebo

JP Morgan analyst Eric Joseph maintains Enanta Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTA#NASDAQ">ENTA</a>) with a Underweight and lowers the price target from $11 to $10.

JP Morgan Maintains Underweight on Enanta Pharma, Lowers Price Target to $10

Enanta Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTA#NASDAQ">ENTA</a>) reported quarterly losses of $(1.07) per share which beat the analyst consensus estimate of $(1.45) by 26.21 percent. The company reported quarterly sales of $18.00 million which beat the analyst consensus estimate of $17.18 million by 4.78 percent. This is a 4.72 percent decrease over sales of $18.89 million the same period last year.

Earnings

Earnings Beats

Enanta Pharma Q3 2024 Adj EPS $(1.07) Beats $(1.45) Estimate, Sales $18.00M Beat $17.18M Estimate

HC Wainwright &amp; Co. analyst Ed Arce maintains Enanta Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTA#NASDAQ">ENTA</a>) with a Buy and lowers the price target from $28 to $27.

HC Wainwright & Co. Maintains Buy on Enanta Pharma, Lowers Price Target to $27

JMP Securities analyst Roy Buchanan maintains Enanta Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTA#NASDAQ">ENTA</a>) with a Market Outperform and lowers the price target from $23 to $22.

JMP Securities Maintains Market Outperform on Enanta Pharma, Lowers Price Target to $22

Enanta Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTA#NASDAQ">ENTA</a>) reported quarterly losses of $(1.47) per share which missed the analyst consensus estimate of $(1.33) by 10.53 percent. This is a 17.88 percent increase over losses of $(1.79) per share from the same period last year. The company reported quarterly sales of $17.054 million which beat the analyst consensus estimate of $16.522 million by 3.22 percent. This is a 4.16 percent decrease over sales of $17.795 million the same period last year.

Earnings Misses

Enanta Pharma Q2 2024 GAAP EPS $(1.47) Misses $(1.33) Estimate, Sales $17.054M Beat $16.522M Estimate

JP Morgan analyst Eric Joseph maintains Enanta Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTA#NASDAQ">ENTA</a>) with a Underweight and lowers the price target from $12 to $11.

JP Morgan Maintains Underweight on Enanta Pharma, Lowers Price Target to $11

Enanta Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTA#NASDAQ">ENTA</a>) reported its Q1 earnings results on Wednesday, February 7, 2024 at 04:01 PM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
Enanta Pharma missed estimated earnings by 32.77%, reporting an EPS of $-1.58 versus an estimate of $-1.19.
Revenue was down $5.58 million from the same period last year.
<h3>Past Earnings Performance</h3>
Last quarter the company beat on EPS by $0.67 which was followed by a 11.52% increase in the share price the next day.
Here's a look at Enanta Pharma's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-2</td>
<td>-2.33</td>
<td>-1.98</td>
<td>-1.59</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-1.33</td>
<td>-1.86</td>
<td>-1.79</td>
<td>-1.39</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>17.50M</td>
<td>18.06M</td>
<td>19.18M</td>
<td>22.57M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>18.93M</td>
<td>18.89M</td>
<td>17.80M</td>
<td>23.59M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Enanta Pharma <a href="https://www.benzinga.com/quote/ENTA/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Recap: Enanta Pharma Q1 Earnings

Enanta Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTA#NASDAQ">ENTA</a>) reported quarterly losses of $(1.58) per share which missed the analyst consensus estimate of $(1.23) by 28.46 percent. This is a 13.67 percent decrease over losses of $(1.39) per share from the same period last year. The company reported quarterly sales of $18.00 million which missed the analyst consensus estimate of $21.95 million by 17.97 percent. This is a 23.67 percent decrease over sales of $23.59 million the same period last year.

Enanta Pharma Q1 2024 GAAP EPS $(1.58) Misses $(1.23) Estimate, Sales $18.00M Miss $21.95M Estimate

Enanta Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTA#NASDAQ">ENTA</a>) is set to give its latest quarterly earnings report on Wednesday, 2024-02-07. Here's what investors need to know before the announcement.
Analysts estimate that Enanta Pharma will report an earnings per share (EPS) of $-1.19. 
Enanta Pharma bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Historical Earnings Performance</h3>
Last quarter the company beat EPS by $0.67, which was followed by a 11.52% increase in the share price the next day.
Here's a look at Enanta Pharma's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-2</td>
<td>-2.33</td>
<td>-1.98</td>
<td>-1.59</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-1.33</td>
<td>-1.86</td>
<td>-1.79</td>
<td>-1.39</td>
</tr>
<tr>
<td>Price Change %</td>
<td>11.52%</td>
<td>-4.24%</td>
<td>-25.66%</td>
<td>-3.54%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1707242533_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Enanta Pharma were trading at $12.37 as of February 05. Over the last 52-week period, shares are down 75.66%. Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. 
<a href="https://www.benzinga.com/quote/ENTA/earnings">To track all earnings releases for Enanta Pharma visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Preview For Enanta Pharma

<ul>
<li>Expansion into Immunology with New Discovery Program of Oral KIT Inhibitors Addressing High Unmet Need in Chronic Spontaneous Urticaria (CSU); Development Candidate Selection Targeted for 2024</li>
<li>Expect Topline Data from at Least One Phase 2 Study of Zelicapavir (EDP-938), an N-Protein Inhibitor in Development to Treat Respiratory Syncytial Virus (RSV), in 3Q 2024, Pending Continuation of a Normal Northern Hemisphere RSV Season</li>
<li>Anticipate Challenge Study Data for EDP-323, an L-Protein Inhibitor in Development to Treat RSV, in 3Q 2024</li>
</ul>

Enanta Pharmaceuticals Will Provide An Update Across Its Pipeline And Plans For 2024 At The 42nd Annual J.P. Morgan Healthcare Conference On Wednesday, January 10, 2024

Jay Luly, President and CEO at Enanta Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTA#NASDAQ">ENTA</a>), reported a large acquisition of company stock options on November 22, according to a new SEC filing.
What Happened: A Form 4 filing from the <a href="https://www.sec.gov/Archives/edgar/data/0001177648/000106299323021379//Archives/edgar/data/1177648/000106299323021379/0001062993-23-021379-index.htm">U.S. Securities and Exchange Commission</a> on Wednesday showed that Luly, President and CEO at Enanta Pharma, a company in the Health Care sector, was just awarded stock options worth 264,000 shares of ENTA. The options give Luly the right to buy the company's stock at $8.99 per share.
Enanta Pharma shares are trading down 11.53% at $8.82 at the time of this writing on Thursday morning. Since the current price is $8.82, this makes Luly's 264,000 shares worth $2,328,480.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>The Importance of Insider Transactions</h3>
Insider transactions shouldn't be used primarily to make an investing decision, however, they can be an important factor for an investor to consider.
In legal terms, an "insider" refers to any officer, director, or beneficial owner of more than ten percent of a company's equity securities registered under Section 12 of the Securities Exchange Act of 1934. This can include executives in the c-suite and large hedge funds. These insiders are required to let the public know of their transactions via a Form 4 filing, which must be filed within two business days of the transaction.
When a company insider makes a new purchase, that is an indication that they expect the stock to rise.
Insider sells, on the other hand, can be made for a variety of reasons, and may not necessarily mean that the seller thinks the stock will go down. 
<h3>Transaction Codes To Focus On</h3>
<a href="https://www.benzinga.com/money/investing-tools">Investors</a> prefer focusing on transactions that take place in the open market, indicated in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S indicates a sale. Transaction code C indicates the conversion of an option, and transaction code A indicates the insider may have been forced to sell shares in order to receive compensation that had been promised upon being hired by the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001177648">Check Out The Full List Of Enanta Pharma's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

Trading Ideas

Enanta Pharma President and CEO Awarded $2.33M Worth of Stock Options

Oppenheimer analyst Jay Olson maintains Enanta Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTA#NASDAQ">ENTA</a>) with a Perform and lowers the price target from $25 to $21.

Oppenheimer Maintains Perform on Enanta Pharma, Lowers Price Target to $21

WIIM

Enanta Pharmaceuticals shares are trading higher after the company reported better-than-expected Q4 revenue results.

Analyst Ed Arce of H.C. Wainwright maintained a Buy rating on Enanta Pharmaceuticals (ENTA – Research Report), retaining the price target of $27.00...

Enanta Pharmaceuticals: Promising Pipeline Progress and a Buy Rating

Enanta Pharmaceuticals (ENTA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on August 5. Analyst Brian S...

Buy Rating Affirmed on Enanta Pharmaceuticals' Promising Drug Pipeline and Strategic Expansion into Immunology

Roanna Ruiz, an analyst from Leerink Partners, maintained the Hold rating on Enanta Pharmaceuticals (ENTA – Research Report). The associated price ...

Enanta Pharmaceuticals: Hold Rating Amid RSV Pipeline Progress and Financial Caution

Oppenheimer analyst Jay Olson maintained a Hold rating on Enanta Pharmaceuticals (ENTA – Research Report) today and set a price target of $16.00. T...

Oppenheimer Sticks to Their Hold Rating for Enanta Pharmaceuticals (ENTA)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Enanta Pharmaceuticals (ENTA – Research Report), Hyperfine (HYPR ...

Analysts Offer Insights on Healthcare Companies: Enanta Pharmaceuticals (ENTA), Hyperfine (HYPR) and Biogen (BIIB)

In a report released today, Roy Buchanan from JMP Securities reiterated a Buy rating on Enanta Pharmaceuticals (ENTA – Research Report), with a pri...

Enanta Pharmaceuticals Gains Buy Rating on Strong Clinical Results for EDP-323

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Enanta Pharmaceuticals (ENTA – Research Report) and ...

Analysts Offer Insights on Healthcare Companies: Enanta Pharmaceuticals (ENTA) and Resmed (RMD)

Leerink Partners analyst Roanna Ruiz maintained a Hold rating on Enanta Pharmaceuticals (ENTA – Research Report) yesterday. The company's shares op...

Enanta Pharmaceuticals (ENTA) Gets a Hold from Leerink Partners

JMP Securities analyst Roy Buchanan reiterated a Buy rating on Enanta Pharmaceuticals (ENTA – Research Report) today and set a price target of $22....

Buy Rating for Enanta Pharmaceuticals Amid Reduced Competition and Promising Drug Trials

In a report released today, Ed Arce from H.C. Wainwright maintained a Buy rating on Enanta Pharmaceuticals (ENTA – Research Report), with a price t...

Buy Rating Affirmed for Enanta Pharmaceuticals on Strong Clinical Trial Outcomes and Promising Pipeline Valuation

BIIB

HYPR

Press Releases

Enanta Pharmaceuticals Announces Data Presentation at ESCMID Global 2024

Enanta Pharmaceuticals to Host Conference Call on May 6 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Second Quarter Ended March 31, 2024

Enanta Pharmaceuticals Announces the Appointment of Matthew P. Kowalsky as Chief Legal Officer

Enanta Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter with Webcast and Conference Call Today at 4:30 p.m. ET

Enanta Pharmaceuticals to Participate at the JMP Securities Life Sciences Conference

Enanta Pharmaceuticals to Participate at the Jefferies Global Healthcare Conference

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter

Enanta Pharmaceuticals to Participate in Investor Conferences in September

Enanta Pharmaceuticals Announces Positive Topline Results for EDP-323 in a Phase 2a Human Challenge Study of Healthy Adults Infected With Respiratory Syncytial Virus (RSV)

Acrivon Therapeutics, Inc. - Common Stock

Acrivon Therapeutics

Amarin Corporation plc - American Depositary Shares, each representing one Ordinary Share

Comments

Enanta Pharma

Vendite allo scoperto

Enanta Pharma (NASDAQ:ENTA) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO